News | February 18, 2009

SAVI Device Expands Access to Shorter Breast Cancer Therapy

Feb 18, 2009 - The SAVI applicator significantly expands the number of women who are able to benefit from breast brachytherapy, according to a new, peer-reviewed journal article in Radiotherapy and Oncology.
The article reports on the first 20 patients to receive radiation therapy for early stage breast cancer with the SAVI applicator, at the University of California, San Diego (UCSD). Authored by Dan Scanderbeg, Ph.D., and others, the article appears in the January 2009 issue of the “Green Journal,” as Radiotherapy and Oncology is known.
The UCSD researchers concluded that SAVI expands the patient population eligible for accelerated partial breast irradiation (APBI), a simpler, much shorter course of radiation therapy following lumpectomy surgery for breast cancer.
In the study, 40 percent of the patients had skin separation (distance between the device and the skin surface) of less than 7 mm. This narrow skin spacing made them ineligible for treatment with “balloon” brachytherapy. SAVI has no skin spacing restrictions, as its multiple catheters allow physicians to carefully direct the dose away from the skin.
“SAVI increases the number of women eligible for APBI beyond what is possible with balloon brachytherapy,” said Dr. Scanderbeg. “The dosimetry with SAVI is phenomenal. The ability to customize the dose allows us to easily contour the radiation and minimize exposure to normal tissue.”
In each of the 20 cases, according to the paper, physicians were able to modulate the dose based on patient-specific anatomy to successfully cover the tumor bed, while sparing healthy tissue. SAVI is a single-entry device that delivers radiation as part of breast conservation therapy. By more precisely targeting radiation therapy, the device treats the tissue where cancer is most likely to recur, while minimizing exposure of structures such as the skin, heart, lungs and ribs.
“The availability of SAVI is a positive development for partial breast irradiation, particularly as preliminary indicators point to the equivalence of APBI with traditional whole breast radiation,” said co-author Catheryn Yashar, M.D., chief of breast and gynecological radiation services at the Moores Cancer Center at UCSD.
“The increasing acceptance of APBI, combined with the availability of more APBI devices and a growing preference among women for a shorter course of radiation therapy, is expanding the number of partial breast cases being performed,” Dr. Yashar said. Instead of the six-week course of treatment required by whole breast radiation, treatment with the SAVI applicator lasts just five days.

For more information: www.SAVI.us

Related Content

Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
Electronic Brachytherapy Comparable to Mohs Surgery in Early-Stage Non-Melanoma Skin Cancer Treatment
News | Brachytherapy Systems | July 20, 2017
July 20, 2017 — Rates of recurrence in early-stage non-melanoma skin cancer (NMSC) patients were virtually identical
Australia's Monash Cancer Centre Treats First Early-Stage Breast Cancer Patient With Xoft System
News | Brachytherapy Systems, Women's Healthcare | May 01, 2017
iCAD Inc. announced the first early-stage breast cancer patient was treated in Australia with intraoperative radiation...
New Clinical Data on Xoft System Presented at American Brachytherapy Society Annual Meeting
News | Brachytherapy Systems, Women's Healthcare | April 20, 2017
iCAD Inc. announced that updated clinical data on the use of intraoperative radiation therapy (IORT) using the Xoft...
iCAD, Xoft Axxent Electronic Brachytherapy System, eBx, 3,000 early-stage breast cancer patients, Miami Breast Cancer Conference
News | Brachytherapy Systems | March 15, 2017
CAD Inc. announced that more than 3,000 early-stage breast cancer patients have been treated with intraoperative...
prostate cancer, radiation therapy, high-dose-rate brachytherapy, HDR, Red Journal study

This is a single-fraction high-dose-rate prostate implant imaging and dosimetry. Image courtesy of Daniel Krauss/American Society for Radiation Oncology (ASTRO)

News | Brachytherapy Systems | March 06, 2017
March 6, 2017 — Results from a new prospective clinical trial indicate high-dose-rate (HDR)...
Elekta, Esteya electronic brachytherapy system, Radiation Oncology Centres, first in Australia, skin cancer
News | Brachytherapy Systems | January 16, 2017
On Dec. 8, 2016, a female patient in her 60s became the first in the Australia/New Zealand region to receive electronic...
iCAD, IORT boost, Xoft Axxent Electronic Brachytherapy System, intraoperative radiation therapy, whole breast radiation, early-stage breast cancer, SABCS 2016
News | Brachytherapy Systems | January 05, 2017
iCAD Inc. announced that researchers presented updated data on the use of intraoperative radiation therapy (IORT) with...
Samsung, Neurologica, BodyTom CT scanner, Willis-Knighton Health System, Louisiana, La., brachytherapy, radiation therapy, ASTRO 2016
News | Computed Tomography (CT) | October 27, 2016
Samsung announced in September that the Willis-Knighton Cancer Center in Shreveport, La., added BodyTom CT, the world’s...
intermediate-risk prostate cancer, brachytherapy versus external beam therapy, radiation therapy, RT, ASTRO 2016
News | Brachytherapy Systems | October 25, 2016
For men with intermediate-risk prostate cancer, radiation treatment with brachytherapy alone can result in similar...
Overlay Init